Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Hutchison And Lilly Expand Collaboration
by Jean-François Tremblay
December 1, 2008
| A version of this story appeared in
Volume 86, Issue 48
Shanghai-based Hutchison MediPharma and Eli Lilly & Co. have agreed to expand their R&D collaboration. Under the new pact, Lilly will provide another oncology target and Hutchison will assume primary responsibility for the identification and selection of suitable clinical drug candidates. Hutchison will get up-front payments, as well as option fees, milestone payments, and royalties on global sales of any resulting drug. Lilly and Hutchison formed their first such pact in August 2007.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X